ID   HT-29R
AC   CVCL_EQ49
DR   cancercelllines; CVCL_EQ49
DR   Cosmic; 1889159
DR   Wikidata; Q54896533
RX   PubMed=21705440;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:132984; RO4927350.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 17
//
RX   PubMed=21705440; DOI=10.1158/0008-5472.CAN-10-4351;
RA   Wang H.-S., Daouti S., Li W.-H., Wen Y., Rizzo C., Higgins B., Packman K.,
RA   Rosen N., Boylan J.F., Heimbrook D., Niu H.-F.;
RT   "Identification of the MEK1(F129L) activating mutation as a potential
RT   mechanism of acquired resistance to MEK inhibition in human cancers
RT   carrying the B-RafV600E mutation.";
RL   Cancer Res. 71:5535-5545(2011).
//